Additional Benefit of Chinese Medicine Formulae Including Dioscoreae rhizome (Shanyao) for Diabetes Mellitus: Current State of Evidence

Background Chinese medicine has been used to treat diabetes symptoms for thousands of years. Dioscoreae rhizome or Shanyao is a Chinese medicinal herb that is routinely used in the treatment of diabetes mellitus (DM). Objective The purpose of this study is to evaluate the evidence of the added benefits and safety of herbal formulae containing Shanyao in clinical studies and the possible mechanisms of Shanyao in the prevention and treatment of DM in experimental studies. Methods We searched nine databases for randomized controlled trials (RCTs) that included Shanyao in the formulae in the treatment of type 2 DM. Furthermore, experimental studies on the prevention and treatment of DM by Shanyao in English- and Chinese-language databases were identified. Results Fifty-three moderate quality RCTs with herbal formulae containing Shanyao were identified. Results from meta-analysis indicated that Shanyao alone or formulae containing Shanyao in addition to conventional treatments could benefit people with type 2 DM in lowering blood glucose, blood lipids and reducing insulin resistance. Moreover, adverse events were significantly lower in the CHM plus conventional group than those in the conventional group. Shanyao may exert the benefit through various mechanisms including inhibition of α-glucosidase and DPP-IV activity, increase of endogenous GLP-1 and immune regulating activities. Conclusion Evidence from this review suggested that there appeared to be added clinical benefits associated with the use of Shanyao for DM, whether as a food supplement or as a CHM combined with hypoglycemic agents with a good safety profile.


INTRODUCTION
Diabetes mellitus (DM) prevalence is growing at an alarming rate worldwide. According to the International Diabetes Federation, about 463 million adults worldwide suffer from DM (1). Among them, China is the country with the largest number of people suffering from DM.
Approximately 95% of the diabetic population is T2DM, followed by type 1 diabetes mellitus, gestational diabetes mellitus, and specific types of diabetes due to other causes (2). Patients with type 1 diabetes mellitus and gestational diabetes mellitus are mainly treated with insulin supplementation and replacement therapy. Specific etiology and pathogenesis of other types of DM vary, and the treatment plan is not unified. Therefore, this study focuses on patients with T2DM.
Epidemiological figures showed that the prevalence of type 2 diabetes mellitus (T2DM) in adults aged 18 and over in China is 10.9% and that of pre-diabetes is 35.7% (3). T2DM is a chronic progressive disease. Da Qing research, a registry cohort study with long term follow-up in China showed that 67.7% of prediabetic people will develop DM after six years without early intervention, but the risk of T2DM in the combined diet and exercise group can be reduced by 42% (4). UK Prospective Diabetes Study suggested that strict glycemic control can reduce the risk of diabetic complications (5). Early active management can be more beneficial for diabetic people, which coincides with the idea of "cure disease before disease onset" in traditional Chinese medicine (TCM).
Treating diabetes by conventional medicine includes oral and injectable hypoglycemic agents. Diabetic patients often need a combination of several drugs. Common concerns of doctors and diabetic patients include hypoglycemia, gastrointestinal discomfort, inconvenience of missing medicines and injectable medicines. The Chinese Diabetes Society (CDS) guidelines of 2017 presented information of TCM for diabetes and recommended the use of TCM (6). In China, it has been observed that doctors in the field of diabetes are also looking for diverse treatments including TCM (6).
In TCM, DM belongs to the category of disease called "xiao ke 消渴". Disease characteristics include thirst, excessive drinking, polyuria, and weight loss. The pathogenesis of DM in TCM is qi and yin deficiency and excessive dryness and heat. Commonly used formulae by TCM practitioners include Liu wei di huang wan 六味地黄丸, Shen qi wan肾气丸, and Ba wei wan八味丸 (7). Shanyao (Dioscoreae rhizome) is the root of Dioscorea opposita Thunb. (8); it is one of the main herbs in the above formulae. Shanyao has been widely used in the treatment of xiao ke消渴or diabetes since the ancient times. It is a popular herb and can also be consumed as a type of food. Active ingredients of Shanyao include polysaccharides, flavonoids, allantoin, choline, and dioscin (9)(10)(11)(12)(13)(14).
This study will review evidence of Shanyao for DM from clinical research and experiment research results from Chineseand English-language databases and present the evidence on added benefits and safety of herbal formula containing Shanyao in clinical studies. Possible mechanisms of Shanyao in the prevention and treatment of DM in experimental studies are also investigated.

Search Strategy
We searched English-and Chinese-language databases and followed the methods outlined in the Cochrane Handbook of Systematic Reviews (15). English-language databases included PubMed, ExcerptaMedica Database (Embase), Cumulative Index of Nursing and Allied Health Literature (CINAHL), Cochrane Central Register of Controlled Trials (CENTRAL), including the Cochrane Library, and Allied and Complementary Medicine Database (AMED); Chinese-language databases included China SinoMed, China National Knowledge Infrastructure (CNKI), Chongqing VIP (CQVIP), and Wanfang. Databases were searched from inception to March 2019. No restrictions were applied.
We also searched reference lists of previous systematic reviews and included studies. Clinical trial registries were also searched including the Australian New Zealand Clinical Trial Registry (ANZCTR), Chinese Clinical Trial Registry (ChiCTR), European Union Clinical Trials Register (EU-CTR) and USA National Institutes of Health register (ClinicalTrials.gov). When required, we contacted trial investigators by email or telephone to obtain data. If we didn't receive a response after four weeks, we marked the unknown information 'not available'.
Protocol of the review was registered with the PROSPERO international prospective register of systematic reviews (CRD 42019145668).
• Or in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dl (11.1 mmol/L). In the absence of unequivocal hyperglycemia, results should be confirmed by repeat testing.

Type of Interventions
CHM, other CM therapies (for example, Chinese medicine dietary therapy), and integrative medicine such as CHM plus hypoglycemic drugs; all the interventions should include Shanyao.

Type of Controls
Conventional therapies recommended in guidelines, including pharmacotherapy, diet therapy and lifestyle interventions.

Data Extraction and Management
Search results were synthesized by removing duplicates, followed by screening of titles and abstracts by LS and YD. Full texts were obtained and screened by two reviewers (LS and YD). Eligible studies satisfying the inclusion criteria were extracted using EpiData software (EpiData Association, Odense, Denmark). LS and YD extracted the data from the included studies independently and double-checked the data to obtain information on authors, publication year, title, journal, participants' characteristics, sample size, methodological details, intervention details, treatment duration, outcome measures, and AEs.

Assessment of Risk of Bias in Included Studies
Risk of bias was assessed using the Cochrane Collaboration's procedures (15). RevMan software (Version 5.2.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012) was used for risk of bias analysis. Items of bias assessed included sequence generation, allocation concealment, blinding of participants, blinding of personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other bias including baseline imbalance and funding. Egger's test was used to assess publication bias. Publication bias was assessed when the subgroup included more than 10 studies.
Risk of bias assessment was conducted by two independent reviewers (LS and YD) and disagreement was resolved by discussion or consultation with a third person (TZ).

Data Analysis
Continuous outcomes were presented as mean difference (MD) with 95% confidence interval (CI) between two groups, whereas dichotomous data were presented as relative risk (RR) with 95% CI. Stata software (13.0) was used for data analysis. Considering heterogeneities among trials, all meta-analyses were performed with random effects model. Heterogeneities between studies was estimated by I 2 . An I 2 score greater than 50% was considered to indicate substantial heterogeneity.
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the quality of evidence.
Pharmacological Research Evidence of Shanyao for DM National Knowledge Infrastructure was undertaken. The search strategy included the terms for Shanyao and its constituent compounds and T2DM. Relevant data were extracted, and a summary of the findings are reported here.

Description of Included Studies Search Results
Our search identified 44,958 articles in the included databases. Fifty-three (53) RCTs involving 4,905 participants were included in the systematic review . The screening process is shown in Figure 1.

Characteristics of the Included Studies
All studies were randomized, parallel-group, controlled trials conducted in China between 2002 and 2018. One study published was in English (44) and the rest in Chinese language. All studies included participants diagnosed in accordance with the 1999 WHO, Chinese Diabetes Society or American Diabetes Association diagnostic criteria for T2DM. In total, 4,905 participants were included in these RCTs; participants' age ranged from 45 to 74 years. Duration of T2DM ranged from 1 week to 20 years. Treatment duration ranged from 2 to 24 weeks. Only one study had a follow-up for 30 weeks (65). Characteristics of included studies are summarized in Table 1.
Fifty-three (53) RCTs assessing CHM as food or integrative medicine for T2DM were identified from the search. 51 studies assessed the combination of CHM with conventional medication (integrative medicine) . One study compared CHM to lifestyle intervention (26); one study compared Chinese medicine diet therapy to lifestyle intervention (25).

Risk of Bias in the Included Studies
The results of the risk of bias judgements are presented in Figure  2 and Figure 3. All included 53 studies were randomized; 15 trials described the process of random sequence generation (25,26,31,32,34,37,38,43,44,46,62,64,65,69,73); two trials implemented allocation concealment (25,37). One study was described as "single-blind" trial with no further details (37). Considering all included outcome measures were objective outcomes, blinding of assessors has low risk of influencing the outcome measures and was judged as low risk of bias in all included studies. Twelve trials did not report on all outcome measures described in the Methods section (37, 40, 44, 53, 56-58, 60, 62, 63, 75, 77), three trials reported on AEs which were not   Subgroup analyses based on comparator drug class, patient age groups, baseline levels of FBG, CM syndrome differentiation, treatment duration, disease duration, and baseline levels of BMI all showed significant differences between groups ( Table 2).
Meta-analysis results showed that as integrative medicine, CHM plus hypoglycemic agents was superior to hypoglycemic agents alone at reducing 2hPG levels at the end of treatment  Table 2).
Meta-analyses showed that CHM in addition to hypoglycemic agents was superior to hypoglycemic agents alone at reducing TG levels in Subgroup analyses by patient age groups, FBG level at baseline, disease duration and BMI levels at baseline showed similar effects on TG ( Table 2). Combined use of CHM with biguanides, insulin, biguanides plus sulfonylureas and biguanides plus a-Glucosidase also produced significant difference between groups; results are like the overall analysis ( Table 2).The combination of CHM to a sulfonylureas did not produce a better result than these agents alone (56, 71) ( Table 2). In studies that provided details on CM syndrome differentiation, adding CHM to hypoglycemic agents showed more benefit in reducing TG levels in patients with qi and yin deficiency (29,31,34,35,37,39,71,77), yin deficiency with excessive heat (43, 64), but not those with spleen deficiency (28) ( Table 2).
CHM plus hypoglycemic agents was superior to hypoglycaemic agents alone [MD −1.11 (−1.44, −0.77); I 2 = 55.0%]. Meta-analysis of results from studies with a low risk of bias for sequence generation showed similar results (34,43,64,65); however, heterogeneity was high. Subgroup analyses based on drug class, baseline levels of FBG, disease duration and baseline levels of BMI all showed significant differences between groups ( Table 2). Subgroup analysis by CM differentiation showed benefit of adding CHM to hypoglycemic group than hypoglycemic agents alone in patients with yin deficiency and excessive heat (33,43,64) (Table 2).
Insulin resistance index. Five RCTs including 434 participants assessed the effects of CHM plus hypoglycemic agents versus hypoglycemic agents alone (27,28,33,54,76). Various hypoglycemic agents were used including metformin, gliclazide, and glimepiride. All studies had a treatment duration of less than or equal to 12 weeks; the shortest treatment duration was 4 weeks.
Meta-analysis showed that CHM plus hypoglycemic agents was not superior to hypoglycemic agents alone [MD 0.09 (−0.26, 0.43), I 2 = 95.0%]. Subgroup analysis by drug class showed benefit in adding CHM to sulfonylureas (33,76) and the combination of biguanides with sulfonylureas (27). No significant difference was observed when CHM was added to biguanides (28,54). Subgroup analysis using age of patients of 41-64 years showed benefit (27,28,33,76). Subgroup analysis based on lower FBG level at baseline (8-10 mmol/L) (27,33,76) showed more benefit but not in the higher subgroup (28,54). In studies that provided information on CM differentiation, meta-analyses showed a benefit in adding CHM to hypoglycemic agents in patients with yin deficiency and excessive heat (33) or spleen deficiency (28). Studies with disease duration of less than 5 years (three RCTs, n = 154) (27,28,33) showed a significant difference between the two groups but not those studies with more than 5 years of disease duration (54,76). Additional subgroup analyses by BMI level at baseline showed difference between groups (28) ( Table 2).
Body Mass Index. Four RCTs including 233 participants assessed the effects of CHM plus hypoglycemic agents versus hypoglycemic agents alone (28,34,62,72). Hypoglycemic agents included biguanides, a-Glucosidase inhibitors and insulins. Specific agents include metformin, acarbose, and insulin. Treatment duration ranged from 8 to 12 weeks.
Meta-analysis results showed that CHM plus hypoglycemic agents was not superior to hypoglycemic agents alone at improving BMI

CHM Diet Therapy Plus Lifestyle Intervention Versus Lifestyle Intervention Alone
One RCT (n = 90) compared CHM as diet therapy (including Shanyao) with lifestyle intervention with a treatment duration of 12 weeks (25). The result showed that combination of Chinese diet therapy using Shanyao and lifestyle intervention was superior to lifestyle intervention alone at reducing FBG and 2hPG levels at

Adverse Events
Out of the 53 studies, 21 studies reported on AEs. Of these, 10 studies provided specific details about the AEs.
Twenty-four AEs were reported in the hypoglycemic drug group. In the hypoglycemic agents group, hypoglycemia (seven cases) was the most common AE. Other AEs included nausea (three cases), headache (two cases), stomach distention (three cases), dyspepsia (two cases), fatigue (two cases), rash (one case), and four other AEs were not described in detail.
One study that compared CHM plus lifestyle intervention to lifestyle intervention reported no AEs (26).

Assessment Using GRADE
An assessment of the quality of the evidence from RCTs was undertaken using GRADE. Interventions, comparators, and outcomes included were selected based on a consensus process. Comparisons were: CHM plus hypoglycemic agents versus hypoglycemic agents, CHM plus lifestyle intervention versus lifestyle intervention and CHM diet therapy plus lifestyle intervention versus lifestyle intervention.
Evidence of Shanyao formulae for T2DM was low to moderate quality ( Table 3). The results showed that oral

Nutritional Study on the Hypoglycemic Effect of Shanyao
Shanyao has been studied to explore its effect on blood glucose as a food. A study indicated that meal A (maize flour meal) was composed of 81% carbohydrate, 3% protein, and 11% fat; meal B (cassava flour meal) was composed of 76% carbohydrate, 3% protein, and 15% fat; while meal C (yam flour meal) was composed of 85% carbohydrate, 2% protein, and 8% fat. Analysis of the results demonstrated a better glycemic response with meals A and C compared with meal B; Shanyao as food may bring more benefits to blood glucose (80). Shanyao's glycemic index has also been investigated. Glycemic index was introduced to rank how slowly or quickly carbohydrate containing foods are digested and increase postprandial blood glucose (24). A study has shown that the actual calorie input may be much lower in Shanyao than in brown rice and white bread, showing that the glycemic value of Shanyao is lower than brown rice (81), which is beneficial for controlling postprandial blood glucose, in turn may benefit diabetic patients.
An experimental research conducted in Brazil showed that Shanyao flour alleviated the consequences of the experimental diabetic disease. It showed that Shanyao flour could control the rise in blood glucose levels in diabetic rats and significantly greater radiodensity of femoral head when compared to DM group, suggesting protection in oxidative agents and postpone bone damage caused by diabetes (82).
Different Shanyao species are present depending on place of production. Dioscorea alata is known to have the highest yields among the Shanyao species with tubers. Dioscorea alata has shown to have higher amylose and total dietary fiber contents, resulting in slower absorption rates and can be particularly useful in diets for diabetics (83).

Pharmacological Effects in Relation to Diabetes of Shanyao and Its Compounds
The pharmacological effects and preventative effects for T2DM of Shanyao or its compounds have been tested in various animal models.
As we mentioned earlier on, a popular formula used for DM is Liu wei di huang wan made up of six herbs including Shanyao. In fructose-rich chow fed rats, after feeding of Liu wei di huang wan at 26 mg/kg for 60 min, reduction in plasma glucose was observed (84). When Shanyao was removed from the mixture, plasma glucose was not modified while this action was not modified by the removal of the other five herbs, indicating important hypoglycemic roles of Shanyao (84). Further, Shanyao produced similar hypoglycemic effects of the Liu wei di huang wan formula, while other herbs in the formula failed to produce the same effects. The authors also investigated the role of Shanyao in improving insulin sensitivity and found that oral administration of Shanyao at 4.2 mg/kg three times daily into streptozotocin-induced diabetic rats increased the response to exogenous insulin (84).
In vehicle-controlled mice and in alloxan-induced diabetic mice, Shanyao decoction concentrate at 300 mg and 600 mg/kg for 10 consecutive days can significantly reduce blood glucose level (85). Further, Shanyao has shown preventative effects on induced blood glucose elevation due to different causes including adrenaline, alloxan, and glucose feeding (85). As for hypoglycemic effects, Shan yao can reduce total cholesterol and triglyceride levels in diabetic rats, showing lipid lowering effects (86).

Polysaccharides
In alloxan-induced diabetic rats and mice, high dose DOTP-80 water-soluble polysaccharide (400 mg/kg) had strong hypoglycemic activity (87). Moreover, water-soluble polysaccharide could increase the level of antioxidant enzyme (superoxide dismutase) activity in alloxan-induced diabetic mice and stimulated an increase in glucose disposal in diabetic rats (87).
In high fat fed streptozotocin-induced type 2 diabetic rats, Shanyao polysaccharide administration significantly reduced fasting plasma glucose levels, increased serum insulin levels, and decreased glucagon levels, showing hypoglycemic effects (88,89). The hypoglycemic effects of Shanyao polysaccharides are comparable to metformin (88,89).
In vitro testing of Shanyao polysaccharide (YP-1) from a variety of Chinese yam revealed that YP-1 could stimulate ConA-induced T lymphocyte proliferation, and its branches are extremely important for the expression of the enhancement of the immunological activity (90). Considering the important role of the immune system in the progression of T2DM, YP-1 could play a part in enhancing immunological activities in T2DM.
Shanyao polysaccharides have shown antioxidant activities. Purified Shanyao polysaccharide could scavenge hydroxyl radical and superoxide radical. Additionally, it displayed inhibitory activity against E. coli, with a minimal inhibitory concentration of 2.5 mg/ml (91).
Dexamethasone-induced insulin resistance glucose/lipid metabolism diabetic mice model was established to evaluate the hypoglycemic effect of different concentrations of HuaiShanyao and different molecular weights of polysaccharide HSY-I, HSY-II, and HSY-III. The results indicated that the Chinese yam polysaccharide mixture had hypoglycemic effect (92).

Saponins and Flavones
The metabolic syndrome is a term for cluster of multiple metabolic risk criteria which is positively correlated with type 2 diabetes mellitus. Shanyao dioscorin interventions exhibit improved metabolic syndrome activities in obese rats, and peptic hydrolysates of Shanyao dioscorin in vitro exhibit DPP IV inhibitory activities (93).
After intragastric administration of dioscoreae flavone in diabetic mice, it was found that blood glucose of diabetic mice was decreased, the amount of drinking water decreased, and the weight of mice recovered (94). Further experiments showed that dioscoreae flavone could inhibit a-glucosidase activity, effectively reduce superoxide dismutase activity and malondialdehyde content in diabetic mice, and have antioxidant effect (94).
Experimental results show that the saponins and flavones of Shanyao had a marked inhibition effect on a-amylase. The kinetic analysis indicates that the inhibition type of saponins and flavones on a-amylase was competitive, and the enzymesubstrate apparent dissociation constant (Km′) of acarbose (the control), saponins, and flavones is 118.86, 79.23, 49.51 mg/ml, respectively (95).

Allantoin
Allantoin is known as the active principle richly contained in Shanyao (Dioscorea spp.). It is identified as an abundant and active component in Shanyao (Dioscorea spp.) (96). Allantoin may improve glucose utilization in the skeletal muscle through b-endorphin dependent-and independent-pathways that decrease plasma glucose in STZ-diabetic rats (97).
Allantoin can increase b-endorphin release through activation of I-2A receptors to lower blood glucose. Also, allantoin can activate I-2B receptors in the skeletal muscle or adipose tissues and brain and others to reduce blood glucose in STZ-diabetic rats. Both actions of allantoin may assist the increase of insulin sensitivity in diabetic rats (98).
Ligands a-Glucosidase inhibitors are widely used in the treatment of patients with T2DM, which delay the absorption of carbohydrates from the small intestine and result in lowered postprandial blood glucose and insulin levels (99). Two ligands identified as 2,4-dimethoxy-6,7-dihydroxyphenanthrene and batatasin I were extracted from Shanyao using a-glucosidase functionalized magnetic nanoparticles as a solid phase extraction absorbent. Their a-glucosidase inhibitory activities were significantly higher than acarbose (100).

Summary of Evidence
In this study, we searched clinical studies and experimental studies to present an overall picture of the evidence for Shanyao and its formulae for additional benefits to conventional therapies in the management of DM. We also explored the possible mechanisms of actions for Shanyao.
This study presents a comprehensive and up-to-date evidence for the treatment of T2DM with Shanyao formulae. A systematic review of 53 randomized controlled trials was identified in English-and Chinese-language databases, and meta-analysis was conducted to evaluate the additive benefits and safety of Shanyao formulae. Systematic evaluation of modern literatures suggested that in terms of controlling blood glucose, blood lipid and improving insulin resistance, traditional Chinese medicine formulae containing Shanyao combined with conventional therapies do show added benefits when compared to hypoglycemic agents and lifestyle intervention alone.
Systematic review of clinical studies indicates that Shanyaocontaining herbal formulae can improve important outcome measures for T2DM including FBG, 2hPG, HbA 1c , TG, TC, and IR in people with T2DM. Further, the adverse events in the herbal formula group are lower than in the control group, suggesting a good safety profile. Taken together, Chinese herbal medicine therapy including Shanyao can be of beneficial for patients with T2DM. The heterogeneity in our meta-analysis was high. We performed a subgroup analysis based on pre-set conditions, but the results of subgroup analysis did not fully explain the source of heterogeneity. Considering different herb usages in different clinical trials, this could be a possible source of heterogeneity in the meta-analysis. Therefore, it is necessary to interpret these results with caution.
The occurrence of DM in the current day and age is closely related to lifestyle change. We found that Shanyao 山药, Fuling 茯苓, Maimendong麦门冬, Shanzhuyu 山茱萸, Haungqi 黄芪, Shengdihuang 生地黄, Gegen 葛根, Danshen 丹参, Tianhuafen 天花粉, and Huanglian 黄连are used more in modern literatures. The use of Chinese herbs that taste sweet and bitter, has the effect of invigorating qi and nourishing yin, infiltrating dampness and solidifying astringency, clearing heat, generating body fluid, and detoxifying. In recent years, the prevalence of diabetes in obese and overweight people has doubled in modern China (6). TCM believes that phlegm-dampness is the basic cause of obesity. An ancient practitioner Zhu Danxi clearly put forward in "Dan Xi Zhi Fa Xin Yao丹溪治法心要" that "people who are obese have excessive dampness and phlegm in the body". Obesity combined with diabetes is characterized by yin deficiency, internal heat, and phlegm dampness. Therefore, modern diabetes treatment focuses on nourishing yin and clearing heat, drying dampness and resolving phlegm.
To sum up the experimental evidence, Shanyao as a food, is rich in dietary fiber with low glycemic index, which is beneficial to improving postprandial blood glucose of diabetic patients. In diabetic animals, Shanyao can reduce blood sugar, regulate blood lipid, resist oxidation and be beneficial to the bone. The main active ingredients of Shanyao can regulate blood glucose by improving insulin resistance, inhibiting a-glucosidase activity, delaying the absorption of glucose in intestine, inhibiting DPP-IV activity, increasing the concentration of endogenous GLP-1, antioxidation and regulating immunity.

Limitations of the Current Review
The included clinical studies also present methodological shortfalls. In randomized clinical trials, appropriate randomization and allocation concealment methods can reduce bias, but only 25.81% of the included studies described the randomization methods, and only 2.58% of the studies described allocation concealment. Inappropriate randomization and allocation concealment may exaggerate the efficacy. Inadequate blinding method can also lead to overestimation of the effect. Chinese herbal medicine has many obstacles to the implementation of blinding in clinical trials due to the herbal preparation and odor; it is easy for participants to identify which group they are in. Active exploration of the preparation of placebo and the implementation of blinding method of traditional Chinese medicine may be a way to solve this problem. In addition, the included studies did not publish study protocols, and the non-standardization of clinical research reports is not helpful to the dissemination and recognition of research results.
Modern literature systematic reviews included the study of traditional Chinese medicine formulae containing Shanyao. The included studies all used Shanyao as part of a traditional Chinese medicine formula for T2DM. Therefore, the results of modern literature analysis do not fully represent the role of Shanyao in the treatment of T2DM in reducing blood sugar, lipid and improving IR.

Implications in Research and Clinical Practice
Future clinical studies should be recommended to design and report data following the items required by the Consolidated Standards of Reporting Trials (CONSORT) (101) and its extensions for herbal medicine and traditional CM (102,103).
Rigorous methodology is recommended when designing future clinical trials with correct methods of sequence generation and allocation concealment. Protocols should be published and be registered to minimize reporting bias and increase transparency in the reporting the results.
The included studies reported outcome measures directly related to blood glucose metabolism, lipid profiles, and b-cell function. As we know, T2DM is a chronic and progressive disease, and those who are affected may have drastic lifestyle changes. Other clinically important outcomes such as quality of life would provide another aspect of understanding the effect of CM therapies for T2DM.
As we all know, T2DM is a progressive and lifelong disease. The included clinical studies had treatments between 2 and 24 weeks with only few studies reporting on follow-up data. Future studies may consider using longer treatment durations and lengthy follow-up period to reflect clinical practice and provide evidence for the long-term effects of CM treatments using Shanyao.
Although we present in the study available experimental evidence for Shanyao, the volume of studies is small compared to other commonly used herbs such as ginseng. More experimental study data will improve the understanding of mechanisms of action of hypoglycemic effects of Shanyao. Results may provide future directions for the development of new and improved hypoglycemic agents.
Finally, this study provides comprehensive information about Shanyao's use for T2DM in clinical studies. At the same time, it explores possible mechanisms through experimental studies, providing evidence of hypoglycemic mechanism of Shanyao at a cellular and animal model levels.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.